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Evaluation of 49-[Methyl-11C]Thiothymidine in a Rodent
Tumor and Inflammation Model
Jun Toyohara1, Philip H. Elsinga2, Kiichi Ishiwata1, JurgenW.A. Sijbesma2, Rudi A.J.O. Dierckx2, and Aren vanWaarde2
1Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; and 2Nuclear Medicine and Molecular
Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
49-[methyl-11C]thiothymidine (11C-4DST) is a novel radiopharma-
ceutical that can be used for tumor imaging because of its rapid
incorporation into DNA as a substrate for DNA synthesis. The in
vivo stability of 11C-4DST is much greater than that of natural
thymidine, because of the presence of a sulfur atom in the 49-
position. Here, we evaluated the tissue kinetics and biodistribution
of 11C-4DST in a rodent tumor and acute sterile inflammation
model in comparison with the previously published biodistribution
data of 39-deoxy-39-18F-fluorothymidine (18F-FLT), 18F-FDG, 11C-
choline, 11C-methionine, and 2 s-receptor ligands in the same
animal model. Methods: C6 tumor cells were implanted subcu-
taneously into the right shoulder and turpentine (0.1 mL) was
injected intramuscularly into the left hind leg of male Wistar rats
11 d and 24 h, respectively, before the scanning day. The animals
were anesthetized with isoflurane, and 11C-4DST (20–50 MBq)
was injected intravenously. A dynamic PET scan was performed
for 60 min with either the shoulder or hind leg region in the field of
view. The animals were sacrificed, and a biodistribution study was
performed. Results: 11C-4DST showed the highest tumor uptake
(standardized uptake value, 4.93) of all radiopharmaceuticals
tested. Its tumor-to-muscle concentration ratio (12.7) was similar
to that of 18F-FDG (13.2). The selectivity of 11C-4DST for tumor as
compared with acute inflammation was high (37.7), comparable to
that of the s-ligand 18F-FE-SA5845 and much higher than that of
18F-FDG (3.5). Rapidly proliferating tissues (tumor and bone mar-
row) showed a steadily increasing uptake. In inflamed muscle,
11C-4DST showed relatively rapid washout, and tracer concentra-
tions in inflamed and noninflamed muscle were not significantly
different at intervals greater than 40 min. Competition of en-
dogenous thymidine for 11C-4DST uptake in target tissues was
negligible, in contrast to competition for 18F-FLT uptake. Thus,
pretreatment of animals with thymidine phosphorylase was
not required before PET with 11C-4DST. Conclusion: In our ro-
dent model, 11C-4DST showed high tumor uptake (sensitivity)
and high tumor selectivity. The different kinetics of 11C-4DST in
rapidly proliferating and inflammatory tissue may allow distinction
between tumor and acute inflammation in a clinical setting. These
promising results for 11C-4DST warrant further investigation in
PET studies in patients with various types of tumors.
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The most widely used radiopharmaceutical in clinical
oncology is currently 18F-FDG. Although the applications of
18F-FDG PET in tumor detection, staging, and therapy eval-
uation are rapidly expanding, 18F-FDG uptake is not tumor-
specific; various forms of inflammatory lesion also take up
18F-FDG and are a major cause of false-positive results. His-
tologic confirmation of 18F-FDG–positive lesions is therefore
required for many types of tumor (1–3). Macrophages, which
invade tumors, especially after therapeutic intervention, can
induce high 18F-FDG uptake and can complicate the interpre-
tation of 18F-FDG PET results (4–6). In addition, decreased
uptake of 18F-FDG is seen in hyperglycemic patients and can
cause false-negative results.
Several lines of evidence suggest that the accumulation of
18F-FDG is based on enhanced glycolysis, which has often
been associated with the growth rate and malignancy of tu-
mor cells. However, all living cells require glucose, and high
levels of 18F-FDG uptake are observed in highly metabolic
inflammatory cells. More specific information on the in vivo
status of tumors may be acquired by the use of a radiophar-
maceutical that is a proliferation marker, as proliferative ac-
tivity is one of the key factors of malignant disease. Various
approaches toward tumor-specific visualization have been
described in the literature, including the use of radiolabeled
amino acids (7), nucleosides (8–10), choline (11–13), and
various receptor ligands (14–17). Strictly speaking, only la-
beled nucleosides that are incorporated into DNA are true
proliferation markers, but the tissue kinetics of radiopharma-
ceuticals tracing amino acid transport, membrane metabo-
lism, enzyme activity, or receptor expression can be used
as a surrogate marker of cellular proliferation if the activity
of such processes is increased in rapidly dividing cells. In
recent years, s-receptor ligands have been proposed as
radiotracers for tumor imaging (14). s-receptors are over-
expressed in rapidly proliferating cells, such as tumor cells
from rodent and human origin. A radioligand for visualiza-
tion of s-receptors with PET could therefore be useful for
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detection of primary tumors and their metastases, for non-
invasive assessment of tumor proliferation status, and for
determination of the s-receptor occupancy of antineoplas-
tic drugs. The 2 s-ligands 11C-SA4503 (selective for the
s1-subtype) and 18F-FE-SA5845 (not selective for a sub-
type) are well characterized for tumor imaging (18,19).
We have been engaged in studies of cell proliferation
imaging based on the DNA incorporation mechanisms of
nucleosides in human tumors (20–24). In recent years, we
have developed 11C-4DST as a new candidate for cell pro-
liferation imaging (25–27). Experiments in a rodent model
indicated that replacement of the 49-position oxygen with
sulfur prevents cleavage of deoxyribose from the nucleo-
side by thymidine phosphorylase, thus conferring resistance
to degradation, which is advantageous for in vivo imaging
(25). This compound was readily incorporated into the
DNA in several mouse tumor models. The standardized
uptake value (SUV) is closely correlated with the gold
standard, that is, incorporation of 14C-thymidine into
DNA (26). Very recently, initial clinical trials of 11C-
4DST PET were reported involving an optimized prepara-
tion of 11C-4DST for injection, safety, radiation dosimetry,
and initial brain tumor imaging in human subjects (27). The
initial findings in a small group of subjects indicated that
11C-4DST PET is suitable for imaging brain tumors, with
acceptable dosimetry and pharmacologic safety at the dose
required for adequate PET imaging. Although the short
physical half-life of 11C places a significant limitation on
commercial distribution and widespread routine clinical
use, it has benefits with regard to lower radiation burden,
diagnosis using multiple tracers, such as 18F-FDG and 11C-
methionine, and repeated scans during the course of ther-
apy. For this reason, there is a significant opportunity for
the use of 11C-4DST in several clinical settings.
To our knowledge, no information is available about the
capability of 11C-4DST to differentiate between malignant and
inflammatory cells. Previously, we developed a rodent model
in which each animal bears a tumor and also has sterile in-
flammation (28,29). This model allows assessment of the tu-
mor selectivity of radiopharmaceuticals, each animal serving
as its own control. In this study, we compared the tissue kinet-
ics and biodistribution of 11C-4DST in a rodent model of tumor
and sterile inflammation with previously published biodistribu-
tion data of 39-deoxy-39-18F-fluorothymidine (18F-FLT), 18F-
FDG, 11C-choline, 11C-methionine, and 2 s-receptor ligands in
the same established animal model.
MATERIALS AND METHODS
Chemicals
11C-4DST was produced by a palladium-mediated Stille cross-
coupling reaction of 5-tributylstannyl-49-thio-29-deoxyuridine
with 11C-methyl iodide (27). The decay-corrected radiochemical
yield was 33% 6 16% (based on 11C-methyl iodide), and specific
activities were greater than 71 TBq/mmol at the end of synthesis.
The product was dissolved in saline, and radiochemical purities
were more than 95%.
Animal Model
Relevant details about our animal model (including PET images
and histologic findings) were reported previously (28). C6 glioma
cells (2 · 106, in a mixture of Matrigel [Becton Dickinson] and
Dulbecco minimal essential medium with 5% fetal calf serum)
were subcutaneously injected into the right shoulder of young
adult male Wistar rats 11 d before tracer injection. Ten days later,
0.1 mL of turpentine was injected intramuscularly into the thigh of
the left hind leg, to produce sterile inflammation within 24 h.
Turpentine injection is an established model of sterile inflamma-
tion (28,30). The animal experiments were performed by licensed
investigators in compliance with the Law of Animal Experiments
of The Netherlands. The protocol was approved by the Committee
on Animal Ethics of the University of Groningen.
Small-Animal PET
Animals were not kept fasting before the PET scan. In most
experiments, 2 animals were scanned simultaneously using a Focus
220 microPET camera (Siemens-Concorde). Three animals were
scanned dynamically with the tumors in the field of view. Another 3
animals were scanned dynamically with the abdomen in the field of
view. The animals were anesthetized with a mixture of isoflurane
and air (inhalation anesthesia, 5% ratio during induction, later
reduced to , 2%). The rats were under anesthesia before tracer
injection. The tracer (11C-4DST) was injected through the penile
vein (22–51 MBq/0.6–1.2 nmol). A list-mode protocol was used
(60 min). Scanning was started during injection of radioactivity in
the lower rat; the upper animal was injected 1 min later.
List-mode data were reframed into a dynamic sequence of 1 ·
15, 1 · 30, 1 · 45, 3 · 60, 1 · 90, 4 · 120, 1 · 210, 2 · 300, 1 ·
450, and 2 · 600 s frames. The data were reconstructed per time
frame using an iterative reconstruction algorithm provided by Sie-
mens (attenuation-weighted 2-dimensional ordered-subset expec-
tation maximization; 4 iterations; 16 subsets; zoom factor, 2). The
final datasets consisted of 95 slices, with a slice thickness of 0.8
mm and an in-plane image matrix of 128 · 128 pixels of size 1 · 1
mm. Datasets were fully corrected for random coincidences, scat-
ter, and attenuation. A separate transmission scan (duration, 515 s)
was acquired for attenuation correction. The scan was made after
the emission scan. Images were smoothed with a gaussian filter
(1.35 mm in both transverse and axial directions).
Small-Animal PET Data Analysis
Three-dimensional regions of interest (ROIs) were manually drawn
around the outside rim of the tumor (thus, necrotic or underperfused
areas of the tumor were included in the tumor ROI) and the bone
marrow hot spot (head of the left humerus in 3 rats; head of the right
femur in the other 3 rats). As tumor and bone marrow had much
higher uptake of 11C-4DST than any other organ in the field of view
(with the exception of the kidneys and urinary bladder), it was rather
easy to define the tumor and bone marrow rim accurately. Tumor
volumes estimated from the PET images corresponded closely to
tumor volumes determined by excision. In contrast, because of the
small size of ROIs, particularly in the humerus, partial-volume effects
will have resulted in underestimation of bone marrow uptake.
In inflamed muscle and control muscle, a 3-dimensional ROI was
carefully drawn around the outside rim of the noninflamed hind leg
(in the coronal images), starting in the plane closest to the animal
bed and proceeding upward until the skeleton was approached. Care
was taken not to include the skeleton in the ROIs. As bone marrow
had much higher uptake of 11C-4DST than any other part of the
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hind leg, this goal was achieved easily. The right hind leg had
a smaller volume than the swollen left hind leg (inflamed thigh).
The volumes (mL) for the noninflamed-muscle ROI were about
50% of the entire volume of the inflamed thigh.
Time–activity curves and volumes (mL) for the ROIs were cal-
culated using standard software (AsiPro, version 6.2.5.0; Siemens-
Concorde). PET SUVs were calculated using measured body weights
and injected doses and assuming a specific gravity of 1 g/mL for
tissue.
Biodistribution Studies
The anesthetized animals were sacrificed after the scanning
period (75 min after radiotracer injection). Blood was collected, and
plasma and cell fraction were obtained from the blood samples by
brief centrifugation (5 min at 1,000g).
Normal tissues (cerebellum, cerebral cortex, rest of brain, white
adipose tissue, bladder, bone, bone marrow, heart, large intestine,
small intestine, kidney, liver, lung, muscle, pancreas, spleen, and
submandibularis) were excised. Urine was collected. The complete
tumor (0.86 6 0.79 g) was excised and separated from muscle and
skin. Inflamed muscle could be distinguished from surrounding
tissue by its pale color and the odor of turpentine. The inflamed
region was excised from the affected thigh. All samples were
weighed, and the radioactivity was measured using a CompuGamma
CS 1282 counter (LKB-Wallac) with application of decay correc-
tion. The results were expressed as dimensionless SUVs (dpm mea-
sured per gram of tissue/dpm injected per gram of body weight).
Tumor-to-plasma and tumor-to-muscle concentration ratios of ra-
dioactivity were also calculated.
The previously published biodistribution data of 18F-FLT, 18F-
FDG, 11C-choline, 11C-methionine, and 2 s-receptor ligands (11C-
SA4503 and 18F-FE-SA5845) (28,29) were used for comparison
with 11C-4DST data.
Statistical Analysis
Differences between the 2 types of lesion were tested for
statistical significance using the 2-sided Student t test. One-way
ANOVA with Dunnett multiple-comparison testing was used for
comparison of each tracer to 11C-4DST. In all analyses, a P value
of less than 0.05 was taken to indicate statistical significance.
Tumor-to-plasma and tumor-to-muscle ratios of tracer uptake were
calculated for each rat. A tumor selectivity index was calculated
for each tracer using the following formula: (tumor SUV – muscle
SUV)/(inflammation SUV – muscle SUV). This figure represents
the tumor-to-inflammation ratio corrected for background activity.
In some animals, the SUV of inflammation was smaller than that
of muscle. This occurred in several of the study groups, that is, 18F-
FLT 1 phosphorylase, 11C-SA4503, 18F-FE-SA5845, and 11C-4-
DST. In such animals, no meaningful value for selectivity index
could be obtained, as it was an infinite or negative value. Therefore,
in this study, selectivity index was calculated from the average SUV
in tumor, inflammation, and muscle for each group rather than from
SUVs for individual rats.
RESULTS
Small-Animal PET Images
Small-animal PET images acquired after injection of 11C-
4DST are presented in Figure 1. High levels of tracer uptake
were observed in tumor and bone marrow. Most activity went
to the kidneys, urinary bladder, and urine. Brain uptake was
negligible. Inflamed muscle and noninflamed muscle showed
low levels of uptake, which were not significantly different
from background.
Kinetics of Radioactivity in Tissues
Figure 2 shows the kinetics of 11C-4DST–derived radio-
activity (PET SUV in the tissues as a function of time). A
steadily increasing level of tracer uptake was observed in
rapidly proliferating tissues, such as tumor (Fig. 2A) and
bone marrow (Fig. 2B). In muscle (nonproliferating tissue),
tracer uptake was low and constant between 20 and 60 min
(Fig. 2C). In inflamed muscle, radioactivity peaked at
5–10 min, followed by washout (Fig. 2C). This initial peak
may have been due to increased blood flow in the inflamed
tissue. At intervals greater than 40 min, tracer uptake levels
were not significantly different between inflamed and
healthy muscle.
Biodistribution Data
Biodistribution data of 11C, acquired 75 min after injection
of 11C-4DST, are presented in Table 1. 11C-4DST showed
physiologic high uptake in rapidly proliferating tissues (bone
marrow, intestine, spleen, and C6 tumor). A large fraction of
the injected dose appeared in urine. Moderate levels of tracer
uptake were found in bone, urinary bladder, liver, and kid-
ney. Low uptake of radioactivity was observed in brain, ad-
ipose tissue, heart, lung, muscle, pancreas, plasma, red blood
cells, submandibular gland, and inflamed muscle. 11C-4DST
uptake was 10 times higher in C6 tumor than in plasma,
FIGURE 1. Small-animal PET images of rat
shoulder region (left) and hind leg region (right)
acquired after injection of 11C-4DST (summed
frames from 10 min to end of scan).
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healthy muscle, and inflamed muscle (Student t test, P ,
0.0001). In contrast, 11C-4DST uptake in inflamed muscle
was not different from that in plasma or healthy muscle
(Student t test, P 5 0.08 and 0.72, respectively).
Sensitivity and Selectivity of 11C-4DST
In our animal model, 11C-4DST showed the highest level
of tumor uptake of all PET tracers tested (Fig. 3A). Tumor-
to-plasma ratios of 11C-4DST (10.0 6 3.1, n 5 6) and 11C-
SA4503 (10.2 6 2.7, n 5 6) were similar and much higher
than those of other tracers (Fig. 3B). 11C-4DST (12.76 2.8,
n 5 6) and 18F-FDG (13.2 6 3.0, n 5 5) showed much
higher tumor-to-muscle contrast than the other tracers (Fig.
3C). 11C-4DST and 18F-FE-SA5845 showed similar tumor
selectivity indices, and the values were the highest among
the compounds investigated (Fig. 3D).
DISCUSSION
This study demonstrated the capability of 11C-4DST to
differentiate malignant from inflammatory cells. In addi-
tion, the tissue kinetics and biodistribution of 11C-4DST
in a rodent model of tumor and sterile inflammation were
compared with previously published biodistribution data
of 18F-FLT, 18F-FDG, 11C-choline, 11C-methionine, and 2
s-receptor ligands in the same established animal model.
In our animal model, 11C-4DST produced promising results.
First, 11C-4DST showed the highest level of tumor uptake,
with high tumor selectivity. Tumor-to-background contrast of
11C-4DST was similar to that of 18F-FDG. Second, 11C-4DST
showed completely different kinetics in tumor and inflamma-
tory tissues. Third, biodistribution data confirmed that 11C-
4DST is a proliferation marker. These encouraging data support
a further clinical pilot study with 11C-4DST in a range of tumor
types.
11C-4DST uptake in the tumor increased steadily with time,
whereas that in inflamed muscle showed slow exponential
clearance after the initial distribution. The kinetics of 11C-
4DST uptake can be expected to be dependent on local blood
flow; nucleoside transport across the cell membrane; intracel-
lular metabolism, including nucleoside phosphorylation; and
DNA incorporation. Currently, it is unknown which is the
rate-limiting step. Preliminary metabolite analysis in mice
showed rapid DNA incorporation of 11C-4DST in proliferat-
ing tissues, such as the duodenum and spleen (Supplemental
Fig. 1; supplemental materials are available online only at
http://jnm.snmjournals.org). The kinetics of DNA incorpora-
tion over a 90-min period can generally be modeled by a rect-
angular hyperbola, with an initial phase of rapid incorporation
followed by a plateau of the curve (Supplemental Fig. 1). The
plateau level was almost 100%: 99% for the duodenum and
94% for the spleen. The times to reach 50% of the respective
plateau levels were rapid: 5.2 min for the duodenum and
7.8 min for the spleen. In contrast, the soluble fraction
(11C-4DST itself, phosphorylated 11C-4DST, and some other
metabolites) was low over 30 min after injection. These data
suggest that the contribution of tissue radioactivity from the
DNA incorporation process overshadows all other processes
(e.g., blood flow, transport, phosphorylation, and dephosphory-
lation) at late phases after 11C-4DST injection. Therefore, in our
small-animal PET study, the steady increases in tissue radioac-
tivity may parallel those of DNA incorporation of 11C-4DST in
the late phase (.30 min). Our inflamed muscle model showed
acute myositis pathology, including necrotic muscle fibers with
massive infiltration of neutrophils, macrophages, and few fibro-
blasts (28). Although this inflammation model shows high met-
FIGURE 2. Kinetics of 11C-4DST–derived radioactivity in C6 tumor
(A), marrow (B), and muscle (C). Error bars indicate SD. s 5 C6
tumor; h 5 humerus; n 5 femur; )5 healthy; ¤5 inflamed.
TUMOR SELECTIVITY OF 11C-4DST • Toyohara et al. 491
abolic activity, the mitotic activity of inflammatory cells is low.
In contrast, C6 tumor tissues showed many mitotic figures (28).
Therefore, the different kinetics in inflammation and tumor
tissues may be due to differences in proliferative activity.
Physiologic accumulation of 11C-4DST to levels greater
than those in plasma was observed in C6 tumors, bone, bone
marrow, the large and small intestine, and the spleen (Table 1).
Many of these organs contain rapidly dividing tissue (malig-
nant cells in the tumor, bone marrow in the skeleton, mucosa in
the intestine). Thus, 11C-4DST behaved as a tracer of cellular
proliferation. This finding is in good accordance with a recent
report suggesting a significant correlation between SUVs of
11C-4DST and proliferative activity of lung tumor lesions (31).
In the present study, 11C-4DST was administered directly
to the animals with no phosphorylase pretreatment. In con-
trast to 18F-FLT, competition of endogenous thymidine for
11C-4DST uptake appeared negligible. Thus, intravenous in-
fusion of thymidine phosphorylase was not required before
PET with 11C-4DST. This makes 11C-4-DST much easier to
apply than 18F-FLT for therapy monitoring in animal tumor
models. Therapy monitoring studies require a high through-
put and longitudinal sequential imaging of each animal. As
thymidine phosphorylase is supplied in potassium phosphate
buffer, a slow rate of infusion was needed in our previous
studies on 18F-FLT to avoid myocardial arrest (28). The
application of thymidine phosphorylase is impossible in lon-
gitudinal studies, as the foreign (bacterial) protein may trig-
ger a response from the immune system of animals, and
secondary or tertiary infusions will have a smaller catalytic
effect than the initial infusion. Moreover, there is a serious
risk of premature loss of animals by cardiac arrest. Fortu-
nately, time-consuming and laborious thymidine phosphory-
lase pretreatments are not required for small-animal PET
scans with 11C-4DST. Furthermore, local thymidine concen-
trations can be increased by cell killing during the course of
therapeutic interventions. Because thymidine competes with
18F-FLT for uptake and trapping in tumor cells, changes in
endogenous thymidine may also obscure the therapeutic ef-
fect in 18F-FLT imaging. Endogenous thymidine may com-
pete with nucleoside tracers for the active site of nucleoside
FIGURE 3. C6 tumor uptake (SUV), target-
to-nontarget ratio, and selectivity index
(tumor-to-inflammation ratio corrected for
background in normal muscle). Data are plot-
ted as mean 6 SD. No SD for selectivity in-
dex can be given because, in some animals,
tracer uptake in inflamed muscle was equiv-
alent to that in contralateral healthy muscle.
4DST5 11C-4DST (n5 6); CHOL5 11C-choline
(n 5 4); FDG 5 18F-FDG (n 5 5); FESA 5
18F-FE-SA5845 (n 5 6); FLT 5 18F-FLT (n 5
3); FLT 1 TP 5 18F-FLT 1 phosphorylase
(n 5 5); MET 5 11C-methionine (n 5 4);
SA 5 11C-SA4503 (n 5 6). Original data of
CHOL, FDG, FESA, FLT, FLT 1 TP, MET,
and SA are from previous reports (28,29).
TABLE 1
SUVs at 75 Minutes After Injection
Tissue 11C-4DST (n 5 6)
Cerebellum 0.20 6 0.04
Cortex 0.16 6 0.03
Rest of brain 0.14 6 0.02
White adipose tissue 0.13 6 0.11
Urinary bladder 1.37 6 0.41
Bone 1.43 6 0.68
Bone marrow 6.97 6 1.99
Heart 0.44 6 0.03
Large intestine 3.40 6 1.08
Small intestine 7.29 6 2.73
Kidney 0.90 6 0.07
Liver 1.10 6 0.11
Lung 0.60 6 0.04
Muscle 0.39 6 0.08
Pancreas 0.45 6 0.09
Plasma 0.49 6 0.03
Red blood cells 0.46 6 0.05
Spleen 2.67 6 0.66
Submandibularis 0.63 6 0.06
C6 tumor 4.93 6 1.42
Inflammation 0.51 6 0.13
Urine 17.09 6 6.59
Bone sample contained marrow. Data are mean 6 SD.
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carriers in cell membranes and also for the active site of
the trapping enzyme, thymidine kinase 1. The difference
between 11C-4DST and 18F-FLT may be due to distinct af-
finities or subtype selectivities of the 2 tracers toward nucle-
oside transporters and thymidine kinase.
Although the usefulness of 11C-4DST for differentiating
between malignant tumors and inflammation was indicated
in our experimental model, our study had an important
limitation. Turpentine-treated muscle was scanned in the
acute phase of inflammation without any contribution of
proliferative inflammatory cells. In contrast, chronic in-
flammatory granulomatous lesions include a Ki-67–positive
(6.3%) lymphocyte fraction (32). Indeed, a patient with
granulomas showed increased 18F-FLT uptake after radia-
tion and chemotherapy (33). A patient with nonspecific in-
terstitial pneumonia had false-positive 18F-FLT findings
(Ki-67 index, 15%) (34). Inflammatory lung diseases are
accompanied by lymphocyte infiltration and involve growth
factors that enhance the proliferation of lymphocytes (35).
As 11C-4DST is a proliferation marker, 11C-4DST may ac-
cumulate as 18F-FLT does in chronic granulomatous lesions
with proliferative inflammation. To confirm 11C-4DST se-
lectivity, further experimental studies with chronic inflam-
mation models will be needed. In addition, we have used
previously published data of other tracers in the same tumor
model for comparison purposes. Although the previous
experiments were performed in the same laboratory and
on the same rodent strain, there is a long interval between
previous studies and the current one. Ideally, simultaneous
studies are needed for a more direct comparison.
CONCLUSION
11C-4DST showed the best characteristics among the
tracers evaluated, combining high tumor uptake (sensitivity)
with tumor selectivity in our established rodent model. The
completely different kinetics of 11C-4DST in rapidly prolif-
erating tissues and inflamed muscle may allow distinction
between tumor and inflammation. The highly promising
results for 11C-4DST warrant further PET studies in patients
with various types of tumor. Further extensive clinical trials
with 11C-4DST PET are required.
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